Trial Review

Technical difficulties have been reported by some users of the search function and is being investigated by technical staff. Thank you for your patience and apologies for any inconvenience caused.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT03568318




Registration number
NCT03568318
Ethics application status
Date submitted
14/06/2018
Date registered
26/06/2018
Date last updated
12/04/2024

Titles & IDs
Public title
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis
Scientific title
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Subjects With Moderate to Severe Atopic Dermatitis
Secondary ID [1] 0 0
2017-005126-37
Secondary ID [2] 0 0
M16-047
Universal Trial Number (UTN)
Trial acronym
AD Up
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Atopic Dermatitis 0 0
Condition category
Condition code
Skin 0 0 0 0
Dermatological conditions
Skin 0 0 0 0
Other skin conditions
Inflammatory and Immune System 0 0 0 0
Other inflammatory or immune system disorders

Intervention/exposure
Study type
Interventional(has expanded access)
Description of intervention(s) / exposure
Treatment: Drugs - Placebo
Treatment: Drugs - Upadacitinib
Treatment: Drugs - Topical corticosteroids (TCS)

Placebo Comparator: Placebo / Upadacitinib + Topical Corticosteroids - Participants will receive placebo orally once a day (QD) for 16 weeks in the double-blind treatment period. At Week 16 participants will be re-randomized to receive either upadacitinib 15 mg or upadacitinib 30 mg QD up to Week 260. Participants will also receive concomitant topical corticosteroids following a step-down regimen through Week 52.

Experimental: Upadacitinib 15 mg QD + Topical Corticosteroids - Participants will receive upadacitinib 15 mg orally once a day for up to 260 weeks. Participants will also receive concomitant topical corticosteroids following a step-down regimen through Week 52.

Experimental: Upadacitinib 30 mg QD + Topical Corticosteroids - Participants will receive upadacitinib 30 mg orally once a day for up to 260 weeks. Participants will also receive concomitant topical corticosteroids following a step-down regimen through Week 52.

Experimental: Long-Term Extension - Participants who reach Week 260 in Studies M16-045, M18-891, and M16-047 will have the opportunity to roll over into the blinded LTE period of M16-047 to continue receiving the same daily dose of upadacitinib for up to Week 524.


Treatment: Drugs: Placebo
Tablets taken orally once a day

Treatment: Drugs: Upadacitinib
Tablets taken orally once a day

Treatment: Drugs: Topical corticosteroids (TCS)
Topical corticosteroids will be applied in a stepdown regimen, starting with medium potency once daily to areas with active lesions until lesions are clear or almost clear, or for 3 consecutive weeks, whichever is shorter; then low potency topical corticosteroids once daily. If lesions return or persist, this step-down approach will be repeated until lesion resolution or evidence of local or systemic topical corticosteroids toxicity.
Recommended TCS include triamcinolone acetonide 0.1% cream or fluocinolone acetonide 0.025% ointment as medium potency topical corticosteroids and hydrocortisone 1% cream as low potency topical corticosteroid.
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Main Study: Percentage of Participants Achieving at Least a 75% Reduction in Eczema Area and Severity Index Score (EASI 75) From Baseline at Week 16
Timepoint [1] 0 0
Baseline and Week 16
Primary outcome [2] 0 0
Main Study: Percentage of Participants Achieving Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) of 0 or 1 With a Reduction From Baseline of = 2 Points at Week 16
Timepoint [2] 0 0
Baseline and Week 16
Secondary outcome [1] 0 0
Main Study: Percentage of Participants Achieving a Reduction of = 4 Points From Baseline in Worst Pruritus Numerical Rating Scale (NRS) at Week 16
Timepoint [1] 0 0
Baseline (last available rolling average before the first dose of study drug) and Week 16
Secondary outcome [2] 0 0
Main Study: Percentage of Participants Achieving a 90% Reduction From Baseline in EASI Score (EASI 90) at Week 16
Timepoint [2] 0 0
Baseline and Week 16
Secondary outcome [3] 0 0
Main Study: Percentage of Participants Achieving a Reduction of = 4 Points From Baseline in Worst Pruritus NRS at Week 4
Timepoint [3] 0 0
Baseline (last available rolling average before the first dose of study drug) and Week 4
Secondary outcome [4] 0 0
Main Study: Percentage of Participants Achieving an EASI 75 Response at Week 4
Timepoint [4] 0 0
Baseline and Week 4
Secondary outcome [5] 0 0
Main Study: Percentage of Participants Achieving an EASI 75 Response at Week 2
Timepoint [5] 0 0
Baseline and Week 2
Secondary outcome [6] 0 0
Main Study: Percentage of Participants Achieving an EASI 90 Response at Week 4
Timepoint [6] 0 0
Baseline and Week 4
Secondary outcome [7] 0 0
Main Study: Percentage of Participants Achieving a 100% Reduction From Baseline in EASI Score (EASI 100) at Week 16
Timepoint [7] 0 0
Baseline and Week 16
Secondary outcome [8] 0 0
Main Study: Percentage of Participants Achieving a Reduction of = 4 Points From Baseline in Worst Pruritus NRS at Week 1
Timepoint [8] 0 0
Baseline (last available rolling average before the first dose of study drug) and Week 1
Secondary outcome [9] 0 0
Main Study: Percent Change From Baseline in Worst Pruritus NRS at Week 16
Timepoint [9] 0 0
Baseline (last available rolling average before the first dose of study drug) and Week 16
Secondary outcome [10] 0 0
Main Study: Percent Change From Baseline in EASI Score at Week 16
Timepoint [10] 0 0
Baseline and Week 16
Secondary outcome [11] 0 0
Adolescents: Percentage of Participants Achieving an EASI 75 Response at Week 16
Timepoint [11] 0 0
Baseline and Week 16
Secondary outcome [12] 0 0
Adolescents: Percentage of Participants Achieving a vIGA-AD of 0 or 1 With a Reduction From Baseline of = 2 Points at Week 16
Timepoint [12] 0 0
Baseline and Week 16
Secondary outcome [13] 0 0
Adolescents: Percentage of Participants Achieving a Reduction of = 4 Points From Baseline in Worst Pruritus NRS at Week 16
Timepoint [13] 0 0
Baseline (last available rolling average before the first dose of study drug) and Week 16
Secondary outcome [14] 0 0
Adolescents: Percentage of Participants Achieving an EASI 90 Response at Week 16
Timepoint [14] 0 0
Baseline and Week 16
Secondary outcome [15] 0 0
Adolescents: Percentage of Participants Achieving a Reduction of = 4 Points From Baseline in Worst Pruritus NRS at Week 4
Timepoint [15] 0 0
Baseline (last available rolling average before the first dose of study drug) and Week 4
Secondary outcome [16] 0 0
Adolescents: Percentage of Participants Achieving an EASI 75 Response at Week 4
Timepoint [16] 0 0
Baseline and Week 4
Secondary outcome [17] 0 0
Adolescents: Percentage of Participants Achieving an EASI 75 Response at Week 2
Timepoint [17] 0 0
Baseline and Week 2
Secondary outcome [18] 0 0
Adolescents: Percentage of Participants Achieving an EASI 90 Response at Week 4
Timepoint [18] 0 0
Baseline and Week 4
Secondary outcome [19] 0 0
Adolescents: Percentage of Participants Achieving an EASI 100 Response at Week 16
Timepoint [19] 0 0
Baseline and Week 16
Secondary outcome [20] 0 0
Adolescents: Percentage of Participants Achieving a Reduction of = 4 Points From Baseline in Worst Pruritus NRS at Week 1
Timepoint [20] 0 0
Baseline (last available rolling average before the first dose of study drug) and Week 1
Secondary outcome [21] 0 0
Adolescents: Percent Change From Baseline in Worst Pruritus NRS at Week 16
Timepoint [21] 0 0
Baseline (last available rolling average before the first dose of study drug) and Week 16
Secondary outcome [22] 0 0
Adolescents: Percent Change From Baseline in EASI Score at Week 16
Timepoint [22] 0 0
Baseline and Week 16

Eligibility
Key inclusion criteria
- Body weight of = 40 kg at Baseline Visit for participants = 12 and < 18 years of age

- Chronic atopic dermatitis (AD) with onset of symptoms at least 3 years prior to
Baseline Visit and subject meets Hanifin and Rajka criteria.

- Active moderate to severe atopic dermatitis defined by Eczema Area and Severity Index
(EASI) = 16, validated Investigator's Global Assessment (vIGA) = 3, = 10% of body
surface area (BSA) with AD involvement, and weekly average of daily Worst Pruritus
numerical rating scale (NRS) = 4.

- Subject has applied a topical emollient (moisturizer) twice daily for at least 7 days
before the Baseline Visit.

- Documented history of inadequate response to topical corticosteroids or topical
calcineurin inhibitor OR documented systemic treatment for AD within 6 months prior to
Baseline Visit
Minimum age
12 Years
Maximum age
75 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Prior exposure to any Janus kinase (JAK) inhibitor

- Unable or unwilling to discontinue current atopic dermatitis (AD) treatments prior to
the study

- Requirement of prohibited medications during the study

- Other active skin diseases or skin infections requiring systemic treatment or would
interfere with appropriate assessment of atopic dermatitis lesions

- Female subject who is pregnant, breastfeeding, or considering pregnancy during the
study

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
9/08/2018
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
16/11/2030
Actual
Sample size
Target
1500
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,QLD,WA
Recruitment hospital [1] 0 0
St George Dermatology & Skin Cancer Centre /ID# 204788 - Kogarah
Recruitment hospital [2] 0 0
Royal North Shore Hospital /ID# 204639 - St Leonards
Recruitment hospital [3] 0 0
Westmead Hospital /ID# 205682 - Westmead
Recruitment hospital [4] 0 0
Veracity Clinical Research /ID# 204793 - Woolloongabba
Recruitment hospital [5] 0 0
Fremantle Dermatology /ID# 205306 - Fremantle
Recruitment postcode(s) [1] 0 0
2217 - Kogarah
Recruitment postcode(s) [2] 0 0
2065 - St Leonards
Recruitment postcode(s) [3] 0 0
2145 - Westmead
Recruitment postcode(s) [4] 0 0
4102 - Woolloongabba
Recruitment postcode(s) [5] 0 0
6160 - Fremantle
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Arizona
Country [3] 0 0
United States of America
State/province [3] 0 0
California
Country [4] 0 0
United States of America
State/province [4] 0 0
Colorado
Country [5] 0 0
United States of America
State/province [5] 0 0
Connecticut
Country [6] 0 0
United States of America
State/province [6] 0 0
Florida
Country [7] 0 0
United States of America
State/province [7] 0 0
Idaho
Country [8] 0 0
United States of America
State/province [8] 0 0
Illinois
Country [9] 0 0
United States of America
State/province [9] 0 0
Indiana
Country [10] 0 0
United States of America
State/province [10] 0 0
Kansas
Country [11] 0 0
United States of America
State/province [11] 0 0
Massachusetts
Country [12] 0 0
United States of America
State/province [12] 0 0
Michigan
Country [13] 0 0
United States of America
State/province [13] 0 0
Missouri
Country [14] 0 0
United States of America
State/province [14] 0 0
Nebraska
Country [15] 0 0
United States of America
State/province [15] 0 0
New Hampshire
Country [16] 0 0
United States of America
State/province [16] 0 0
New Jersey
Country [17] 0 0
United States of America
State/province [17] 0 0
New York
Country [18] 0 0
United States of America
State/province [18] 0 0
Ohio
Country [19] 0 0
United States of America
State/province [19] 0 0
Oklahoma
Country [20] 0 0
United States of America
State/province [20] 0 0
Oregon
Country [21] 0 0
United States of America
State/province [21] 0 0
Pennsylvania
Country [22] 0 0
United States of America
State/province [22] 0 0
Rhode Island
Country [23] 0 0
United States of America
State/province [23] 0 0
Tennessee
Country [24] 0 0
United States of America
State/province [24] 0 0
Texas
Country [25] 0 0
United States of America
State/province [25] 0 0
Utah
Country [26] 0 0
United States of America
State/province [26] 0 0
Virginia
Country [27] 0 0
United States of America
State/province [27] 0 0
Washington
Country [28] 0 0
United States of America
State/province [28] 0 0
Wisconsin
Country [29] 0 0
Austria
State/province [29] 0 0
Oberoesterreich
Country [30] 0 0
Austria
State/province [30] 0 0
Tirol
Country [31] 0 0
Austria
State/province [31] 0 0
Wien
Country [32] 0 0
Belgium
State/province [32] 0 0
Bruxelles-Capitale
Country [33] 0 0
Belgium
State/province [33] 0 0
Oost-Vlaanderen
Country [34] 0 0
Belgium
State/province [34] 0 0
Loverval
Country [35] 0 0
Canada
State/province [35] 0 0
Alberta
Country [36] 0 0
Canada
State/province [36] 0 0
Newfoundland and Labrador
Country [37] 0 0
Canada
State/province [37] 0 0
Nova Scotia
Country [38] 0 0
Canada
State/province [38] 0 0
Ontario
Country [39] 0 0
Canada
State/province [39] 0 0
Quebec
Country [40] 0 0
China
State/province [40] 0 0
Beijing
Country [41] 0 0
China
State/province [41] 0 0
Guangdong
Country [42] 0 0
China
State/province [42] 0 0
Hubei
Country [43] 0 0
China
State/province [43] 0 0
Liaoning
Country [44] 0 0
China
State/province [44] 0 0
Zhejiang
Country [45] 0 0
China
State/province [45] 0 0
Changsha
Country [46] 0 0
China
State/province [46] 0 0
Shanghai
Country [47] 0 0
Czechia
State/province [47] 0 0
Plzen
Country [48] 0 0
Czechia
State/province [48] 0 0
Prague
Country [49] 0 0
Czechia
State/province [49] 0 0
Praha
Country [50] 0 0
France
State/province [50] 0 0
Alpes-Maritimes
Country [51] 0 0
France
State/province [51] 0 0
Bouches-du-Rhone
Country [52] 0 0
France
State/province [52] 0 0
Centre-Val De Loire
Country [53] 0 0
France
State/province [53] 0 0
Bordeaux
Country [54] 0 0
France
State/province [54] 0 0
Reims
Country [55] 0 0
Germany
State/province [55] 0 0
Baden-Wuerttemberg
Country [56] 0 0
Germany
State/province [56] 0 0
Hessen
Country [57] 0 0
Germany
State/province [57] 0 0
Nordrhein-Westfalen
Country [58] 0 0
Germany
State/province [58] 0 0
Rheinland-Pfalz
Country [59] 0 0
Germany
State/province [59] 0 0
Schleswig-Holstein
Country [60] 0 0
Germany
State/province [60] 0 0
Bonn
Country [61] 0 0
Germany
State/province [61] 0 0
Hamburg
Country [62] 0 0
Germany
State/province [62] 0 0
Hannover
Country [63] 0 0
Germany
State/province [63] 0 0
Mainz
Country [64] 0 0
Germany
State/province [64] 0 0
Munich
Country [65] 0 0
Greece
State/province [65] 0 0
Attiki
Country [66] 0 0
Greece
State/province [66] 0 0
Thessaloniki
Country [67] 0 0
Hong Kong
State/province [67] 0 0
Hong Kong
Country [68] 0 0
Hungary
State/province [68] 0 0
Bekes
Country [69] 0 0
Hungary
State/province [69] 0 0
Csongrad
Country [70] 0 0
Hungary
State/province [70] 0 0
Hajdu-Bihar
Country [71] 0 0
Hungary
State/province [71] 0 0
Debrecen
Country [72] 0 0
Hungary
State/province [72] 0 0
Szolnok
Country [73] 0 0
Ireland
State/province [73] 0 0
Dublin
Country [74] 0 0
Ireland
State/province [74] 0 0
Cork
Country [75] 0 0
Ireland
State/province [75] 0 0
Waterford
Country [76] 0 0
Israel
State/province [76] 0 0
HaDarom
Country [77] 0 0
Israel
State/province [77] 0 0
Tel-Aviv
Country [78] 0 0
Israel
State/province [78] 0 0
Afula
Country [79] 0 0
Israel
State/province [79] 0 0
Petakh Tikva
Country [80] 0 0
Italy
State/province [80] 0 0
Lazio
Country [81] 0 0
Italy
State/province [81] 0 0
Milano
Country [82] 0 0
Italy
State/province [82] 0 0
Ancona
Country [83] 0 0
Italy
State/province [83] 0 0
Catania
Country [84] 0 0
Italy
State/province [84] 0 0
Milan
Country [85] 0 0
Italy
State/province [85] 0 0
Napoli
Country [86] 0 0
Japan
State/province [86] 0 0
Aichi
Country [87] 0 0
Japan
State/province [87] 0 0
Fukuoka
Country [88] 0 0
Japan
State/province [88] 0 0
Hiroshima
Country [89] 0 0
Japan
State/province [89] 0 0
Hokkaido
Country [90] 0 0
Japan
State/province [90] 0 0
Hyogo
Country [91] 0 0
Japan
State/province [91] 0 0
Kanagawa
Country [92] 0 0
Japan
State/province [92] 0 0
Kyoto
Country [93] 0 0
Japan
State/province [93] 0 0
Miyagi
Country [94] 0 0
Japan
State/province [94] 0 0
Osaka
Country [95] 0 0
Japan
State/province [95] 0 0
Tochigi
Country [96] 0 0
Japan
State/province [96] 0 0
Tokyo
Country [97] 0 0
Netherlands
State/province [97] 0 0
Zuid-Holland
Country [98] 0 0
Netherlands
State/province [98] 0 0
Amsterdam
Country [99] 0 0
Netherlands
State/province [99] 0 0
Groningen
Country [100] 0 0
Netherlands
State/province [100] 0 0
Utrecht
Country [101] 0 0
New Zealand
State/province [101] 0 0
Hamilton
Country [102] 0 0
Norway
State/province [102] 0 0
Hordaland
Country [103] 0 0
Norway
State/province [103] 0 0
Troms
Country [104] 0 0
Norway
State/province [104] 0 0
Oslo
Country [105] 0 0
Puerto Rico
State/province [105] 0 0
Caguas
Country [106] 0 0
Puerto Rico
State/province [106] 0 0
San Juan
Country [107] 0 0
Slovakia
State/province [107] 0 0
Banska Bystrica
Country [108] 0 0
Slovakia
State/province [108] 0 0
Martin
Country [109] 0 0
Slovakia
State/province [109] 0 0
Nove Zamky
Country [110] 0 0
Slovakia
State/province [110] 0 0
Presov
Country [111] 0 0
Spain
State/province [111] 0 0
Cadiz
Country [112] 0 0
Spain
State/province [112] 0 0
Alicante
Country [113] 0 0
Spain
State/province [113] 0 0
Barcelona
Country [114] 0 0
Spain
State/province [114] 0 0
Madrid
Country [115] 0 0
Sweden
State/province [115] 0 0
Skane Lan
Country [116] 0 0
Sweden
State/province [116] 0 0
Vastra Gotalands Lan
Country [117] 0 0
Sweden
State/province [117] 0 0
Stockholm
Country [118] 0 0
United Kingdom
State/province [118] 0 0
London, City Of
Country [119] 0 0
United Kingdom
State/province [119] 0 0
Oxfordshire
Country [120] 0 0
United Kingdom
State/province [120] 0 0
Scotland
Country [121] 0 0
United Kingdom
State/province [121] 0 0
Leeds

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
AbbVie
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The objective of this study is to assess the efficacy and safety of upadacitinib combined
with topical corticosteroids (TCS) for the treatment of adolescent and adult participants
with moderate to severe atopic dermatitis (AD) who are candidates for systemic therapy.
Trial website
https://clinicaltrials.gov/ct2/show/NCT03568318
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
ABBVIE INC.
Address 0 0
AbbVie
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT03568318